Nurix Therapeutics (NRIX) AI Stock Analysis

• Market Cap: $697.22M
• Dividend Yield: N/A
• Average Volume (3M): 757.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.20
• Revenue Growth: 41.86%
• EPS Growth: 10.48%
• Country: US
• Employees: 286
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.52
• Shares Outstanding: 76,449,356
• 10 Day Avg. Volume: 771,903
• 30 Day Avg. Volume: 757,208
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 5.18
• Enterprise Value/Gross Profit: 5.73
• Enterprise Value/Ebitda: -2.10
• 1Y Price Target: $28.77
• Price Target Upside: 215.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 47 Neutral
• Price Target: $9.00 ▼(-1.32% Downside)

Nurix Therapeutics faces significant profitability and valuation challenges, with technical indicators pointing to bearish momentum. However, recent positive corporate events related to clinical trials provide a potential upside, highlighting strategic advancements in their product pipeline.

Positive Factors

Financial Performance

Nurix reported $44.1M in collaboration/license revenue, exceeding previous estimates of $25.0M.

Financial Stability

Nurix ended F2Q25 with ~$485.8M in cash and cash equivalents, providing an operational runway into 1H27.

Investment Opportunities

Shares remain cheap, and offer an attractive entry point for long-term investors.

Negative Factors

Capital Overhang

There is a capital overhang that has limited upside for shares, which needs to be addressed for shares to work meaningfully higher.

Operating Expenses

Analyst slightly lowers the 12-month price target to $34 from $36 due to greater operating expenses.

Regulatory Clarity

Shares are down -35% as investors await clarity on the future regulatory strategy for bexdeg in CLL.

Nurix Therapeutics Business Overview & Revenue Model

Company Description

Nurix Therapeutics (NRIX) is a biopharmaceutical company focused on discovering and developing innovative therapies for cancer and other diseases through its proprietary DELigase platform, which targets protein degradation pathways. The company operates in the biotechnology sector, emphasizing the development of small molecules that harness the body's own cellular machinery to selectively degrade disease-causing proteins. Nurix's core products include drug candidates aimed at various cancers, leveraging its unique approach to modulate the immune system and provide treatment options with potentially improved efficacy and safety profiles.

How the Company Makes Money

Nurix Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which often involve upfront payments, milestone payments, and royalties based on future sales of drugs developed from their technology. The company also engages in research and development agreements, which can provide additional funding. Milestone payments are tied to the achievement of specific development goals, such as advancing a drug candidate into clinical trials or obtaining regulatory approval. Furthermore, if any of their drug candidates successfully reach the market, Nurix stands to benefit from royalties on sales, creating a sustainable revenue stream linked to the commercial success of its innovative therapies.

Nurix Therapeutics Financial Statement Overview

Summary

Nurix Therapeutics faces significant challenges in achieving profitability and sustainable cash flow. Despite a strong equity position with minimal leverage, ongoing operational and profitability concerns are evident in the income statement and cash flow statement. Improvement in revenue growth and cost management is essential for enhancing financial health.

Income Statement

Nurix Therapeutics has shown an inconsistent revenue trend with notable fluctuations. The TTM data indicates a gross profit margin of 85.39%, reflecting efficient cost management relative to revenue. However, the company is struggling with profitability, as indicated by a negative net profit margin of -369.41%. EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.

Balance Sheet

The company displays a strong equity position, with an equity ratio of 78.19% in the TTM, indicating low leverage and a strong reliance on equity financing. However, the debt-to-equity ratio stands at 0.06, which is relatively low, suggesting minimal debt use. Return on Equity (ROE) remains negative due to ongoing net losses, impacting overall financial stability.

Cash Flow

Operating cash flow is negative, reflecting ongoing cash burn from operations. The free cash flow growth rate remains concerning, with continued negative figures indicating challenges in generating cash from operations. However, the operating cash flow to net income ratio is slightly improving, suggesting potential operational efficiency gains.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	88.38M	54.55M	76.99M	38.63M	29.75M	17.82M
Gross Profit	79.93M	38.12M	63.33M	27.82M	23.67M	-48.67M
EBITDA	-217.88M	-196.60M	-141.41M	-173.06M	-111.80M	-62.80M
Net Income	-207.32M	-193.57M	-143.95M	-180.36M	-117.19M	-43.24M
Balance Sheet
Total Assets	591.55M	669.34M	355.60M	416.76M	476.77M	396.34M
Cash, Cash Equivalents and Short-Term Investments	485.78M	609.58M	287.91M	309.14M	295.72M	281.15M
Total Debt	51.93M	28.30M	30.61M	11.96M	13.04M	0.00
Total Liabilities	143.95M	142.35M	155.10M	113.06M	134.47M	106.07M
Stockholders Equity	447.60M	526.99M	200.49M	303.70M	342.30M	290.27M
Cash Flow
Free Cash Flow	-225.79M	-181.86M	-89.77M	-172.05M	-90.03M	-4.63M
Operating Cash Flow	-215.18M	-172.58M	-81.36M	-159.81M	-84.36M	-80.00K
Investing Cash Flow	-65.12M	-257.71M	68.30M	27.20M	-108.25M	-254.40M
Financing Cash Flow	247.77M	485.67M	3.22M	117.19M	153.88M	339.02M

Nurix Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Negative. The current price of 9.12 is below the 20-day moving average (MA) of 9.79, below the 50-day MA of 11.02, and below the 200-day MA of 14.27, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 35.82 is Neutral, neither overbought nor oversold. The STOCH value of 16.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRIX.

Nurix Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IOVA	55 Neutral	$796.08M	―	-53.16%	―	636.99%	27.10%
NTLA	55 Neutral	$1.25B	―	-56.95%	―	14.99%	14.42%
RCUS	54 Neutral	$1.15B	―	-50.34%	―	6.07%	-2.28%
MLYS	53 Neutral	$2.52B	―	-63.21%	―	―	-32.33%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
ARVN	50 Neutral	$558.71M	―	-35.41%	―	―	―
NRIX	47 Neutral	$697.22M	―	-50.67%	―	41.86%	10.48%

Nurix Therapeutics Corporate Events

Nurix Therapeutics to Discuss Bexobrutideg Developments

Nurix Therapeutics announced plans to meet with securities analysts and investors starting September 3, 2025, to discuss updates on their clinical development plans for bexobrutideg. This drug is being tested in a Phase 1 trial and has shown potential in treating B cell malignancies by overcoming resistance mutations and crossing the blood-brain barrier. The announcement highlights the company’s strategic focus on advancing treatments for unmet medical needs, potentially impacting its market positioning and offering significant implications for stakeholders.

Nurix Therapeutics Announces Leadership Change in Committee

On August 19, 2025, Nurix Therapeutics announced that Lori A. Kunkel, M.D., would resign from her position as a Class III director and chair of the Clinical and Commercialization Committee, effective September 1, 2025. Her resignation was not due to any disagreements with the company. In response, the board appointed Roy D. Baynes to take over as chair of the Clinical and Commercialization Committee, also effective September 1, 2025.

Nurix Therapeutics Announces Positive Phase 1 Trial Results

On June 12, 2025, Nurix Therapeutics announced positive clinical data from its Phase 1 trial of bexobrutideg (NX-5948) at the European Hematology Association Congress. The data showed an objective response rate of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 84.2% in patients with Waldenström macroglobulinemia (WM), with bexobrutideg demonstrating a favorable safety profile and potential as a treatment for patients with high unmet medical needs. The company plans to initiate pivotal trials in 2025, reinforcing its scientific leadership in targeted protein degradation.